Clinical Trial Update: Bevacizumab Biosimilar Plus FOLFOX4 in the Treatment of Recurrent HCC After Liver Transplantation [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bevacizumab biosimilar with FOLFOX4 for recurrent hepatocellular carcinoma after liver transplantation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Liver Transplantation

Drugs mentioned

• Bevacizumab biosimilar (Bevacizumab)
• FOLFOX4 (Folinic acid (Leucovorin), Fluorouracil (5-FU), Oxaliplatin)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Post-orthotopic Liver Transplantation, Hepatocellular Carcinoma Recurrent | Phase 2 | Status: UNKNOWN